FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007127557> ?p ?o ?g. }

• W2007127557 endingPage "5011" @default.
• W2007127557 startingPage "5002" @default.
• W2007127557 abstract "ABSTRACT A major hurdle to killing Epstein-Barr virus (EBV)-infected tumor cells using oncolytic therapy is the presence of a substantial fraction of EBV-infected cells that does not support the lytic phase of EBV despite exposure to lytic cycle-promoting agents. To determine the mechanism(s) underlying this refractory state, we developed a strategy to separate lytic from refractory EBV-positive (EBV + ) cells. By examining the cellular transcriptome in separated cells, we previously discovered that high levels of host STAT3 (signal transducer and activator of transcription 3) curtail the susceptibility of latently infected cells to lytic cycle activation signals. The goals of the present study were 2-fold: (i) to determine the mechanism of STAT3-mediated resistance to lytic activation and (ii) to exploit our findings to enhance susceptibility to lytic activation. We therefore analyzed our microarray data set, cellular proteomes of separated lytic and refractory cells, and a publically available STAT3 chromatin immunoprecipitation sequencing (ChIP-Seq) data set to identify cellular PCBP2 [poly(C)-binding protein 2], an RNA-binding protein, as a transcriptional target of STAT3 in refractory cells. Using Burkitt lymphoma cells and EBV + cell lines from patients with hypomorphic STAT3 mutations, we demonstrate that single cells expressing high levels of PCBP2 are refractory to spontaneous and induced EBV lytic activation, STAT3 functions via cellular PCBP2 to regulate lytic susceptibility, and suppression of PCBP2 levels is sufficient to increase the number of EBV lytic cells. We expect that these findings and the genome-wide resources that they provide will accelerate our understanding of a longstanding mystery in EBV biology and guide efforts to improve oncolytic therapy for EBV-associated cancers. IMPORTANCE Most humans are infected with Epstein-Barr virus (EBV), a cancer-causing virus. While EBV generally persists silently in B lymphocytes, periodic lytic (re)activation of latent virus is central to its life cycle and to most EBV-related diseases. However, a substantial fraction of EBV-infected B cells and tumor cells in a population is refractory to lytic activation. This resistance to lytic activation directly and profoundly impacts viral persistence and the effectiveness of oncolytic therapy for EBV + cancers. To identify the mechanisms that underlie susceptibility to EBV lytic activation, we used host gene and protein expression profiling of separated lytic and refractory cells. We find that STAT3, a transcription factor overactive in many cancers, regulates PCBP2, a protein important in RNA biogenesis, to regulate susceptibility to lytic cycle activation signals. These findings advance our understanding of EBV persistence and provide important leads on devising methods to improve viral oncolytic therapies." @default.
• W2007127557 created "2016-06-24" @default.
• W2007127557 creator A5015173460 @default.
• W2007127557 creator A5018503049 @default.
• W2007127557 creator A5028548162 @default.
• W2007127557 creator A5065276270 @default.
• W2007127557 creator A5065925405 @default.
• W2007127557 creator A5070606861 @default.
• W2007127557 creator A5075073873 @default.
• W2007127557 creator A5085285326 @default.
• W2007127557 date "2015-05-01" @default.
• W2007127557 modified "2023-10-13" @default.
• W2007127557 title "Cellular STAT3 Functions via PCBP2 To Restrain Epstein-Barr Virus Lytic Activation in B Lymphocytes" @default.
• W2007127557 cites W1542343912 @default.
• W2007127557 cites W1544691147 @default.
• W2007127557 cites W1548640328 @default.
• W2007127557 cites W1979401674 @default.
• W2007127557 cites W1980480652 @default.
• W2007127557 cites W1986675733 @default.
• W2007127557 cites W1990299806 @default.
• W2007127557 cites W1991043452 @default.
• W2007127557 cites W1992879612 @default.
• W2007127557 cites W2006646444 @default.
• W2007127557 cites W2016063153 @default.
• W2007127557 cites W2021743722 @default.
• W2007127557 cites W2038437697 @default.
• W2007127557 cites W2046500646 @default.
• W2007127557 cites W2049236749 @default.
• W2007127557 cites W2051369825 @default.
• W2007127557 cites W2052908887 @default.
• W2007127557 cites W2058015595 @default.
• W2007127557 cites W2059572899 @default.
• W2007127557 cites W2062050057 @default.
• W2007127557 cites W2064786652 @default.
• W2007127557 cites W2071964308 @default.
• W2007127557 cites W2074341138 @default.
• W2007127557 cites W2077721448 @default.
• W2007127557 cites W2091947752 @default.
• W2007127557 cites W2099077578 @default.
• W2007127557 cites W2101560397 @default.
• W2007127557 cites W2106806242 @default.
• W2007127557 cites W2109623522 @default.
• W2007127557 cites W2113704699 @default.
• W2007127557 cites W2118483952 @default.
• W2007127557 cites W2122438081 @default.
• W2007127557 cites W2128047935 @default.
• W2007127557 cites W2128551987 @default.
• W2007127557 cites W2132799851 @default.
• W2007127557 cites W2135401517 @default.
• W2007127557 cites W2137319242 @default.
• W2007127557 cites W2139915703 @default.
• W2007127557 cites W2150037519 @default.
• W2007127557 cites W2158217645 @default.
• W2007127557 cites W2522939951 @default.
• W2007127557 doi "https://doi.org/10.1128/jvi.00121-15" @default.
• W2007127557 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4403452" @default.
• W2007127557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25717101" @default.
• W2007127557 hasPublicationYear "2015" @default.
• W2007127557 type Work @default.
• W2007127557 sameAs 2007127557 @default.
• W2007127557 citedByCount "30" @default.
• W2007127557 countsByYear W20071275572015 @default.
• W2007127557 countsByYear W20071275572016 @default.
• W2007127557 countsByYear W20071275572017 @default.
• W2007127557 countsByYear W20071275572018 @default.
• W2007127557 countsByYear W20071275572019 @default.
• W2007127557 countsByYear W20071275572020 @default.
• W2007127557 countsByYear W20071275572021 @default.
• W2007127557 countsByYear W20071275572023 @default.
• W2007127557 crossrefType "journal-article" @default.
• W2007127557 hasAuthorship W2007127557A5015173460 @default.
• W2007127557 hasAuthorship W2007127557A5018503049 @default.
• W2007127557 hasAuthorship W2007127557A5028548162 @default.
• W2007127557 hasAuthorship W2007127557A5065276270 @default.
• W2007127557 hasAuthorship W2007127557A5065925405 @default.
• W2007127557 hasAuthorship W2007127557A5070606861 @default.
• W2007127557 hasAuthorship W2007127557A5075073873 @default.
• W2007127557 hasAuthorship W2007127557A5085285326 @default.
• W2007127557 hasBestOaLocation W20071275571 @default.
• W2007127557 hasConcept C101762097 @default.
• W2007127557 hasConcept C104317684 @default.
• W2007127557 hasConcept C134320426 @default.
• W2007127557 hasConcept C150194340 @default.
• W2007127557 hasConcept C154317977 @default.
• W2007127557 hasConcept C159047783 @default.
• W2007127557 hasConcept C182615771 @default.
• W2007127557 hasConcept C202751555 @default.
• W2007127557 hasConcept C2522874641 @default.
• W2007127557 hasConcept C2776409557 @default.
• W2007127557 hasConcept C2780727368 @default.
• W2007127557 hasConcept C2781295983 @default.
• W2007127557 hasConcept C502942594 @default.
• W2007127557 hasConcept C54355233 @default.
• W2007127557 hasConcept C73588182 @default.
• W2007127557 hasConcept C82210918 @default.
• W2007127557 hasConcept C86803240 @default.
• W2007127557 hasConcept C95444343 @default.
• W2007127557 hasConceptScore W2007127557C101762097 @default.

• next